{
  "id": "63f749cf33942b094c00000a",
  "type": "summary",
  "question": "What is the mechanism of action of Zanidatamab?",
  "ideal_answer": "Zanidatamab is a humanised, bispecific monoclonal antibody directed against two non-overlapping domains of HER2.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/36000541",
    "http://www.ncbi.nlm.nih.gov/pubmed/36102999",
    "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
    "http://www.ncbi.nlm.nih.gov/pubmed/34626563",
    "http://www.ncbi.nlm.nih.gov/pubmed/36472472",
    "http://www.ncbi.nlm.nih.gov/pubmed/36459075"
  ],
  "snippets": [
    {
      "text": "Zanidatamab and tislelizumab are novel monoclonal antibodies targeting HER2 and PD-1, respectively, and have shown encouraging antitumor activity in early phase studies in multiple cancers, including GEA. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36000541",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36102999",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Zanidatamab is a humanised, bispecific monoclonal antibody directed against two non-overlapping domains of HER2. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zanidatamab is safe with preliminary efficacy in multiple HER2-expressing and HER2-amplified tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36459075",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Early phase trials of dabrafenib plus trametinib (BRAF and MEK inhibition) and zanidatamab (a bispecific HER2-antibody) have yielded encouraging response rates.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34626563",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Of those in late-stage development, marketing application submissions for at least 23 may occur by the end of 2023, of which 5 are bispecific (odronextamab, erfonrilimab, linvoseltamab, zanidatamab, and talquetamab) and 2 are ADCs (datopotamab deruxtecan, and tusamitamab ravtansine).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36472472",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}